Latest Headlines

  1. BD Launches New Cell Analyzer Configurations To Bring Cutting-Edge Capabilities To Labs Of All Sizes 12/5/2025

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.

  2. Liebherr Expands Scientific And Healthcare Portfolio With New Generation Of Undercounter Appliances 12/2/2025

    Liebherr USA, Co., Refrigerators and Freezers Division is proud to introduce its latest line of undercounter refrigerators and freezers, specially designed for the safe storage of temperature-sensitive substances, pharmaceutical products and flammable materials.

  3. Perspectum And InHealth Announce National Diagnostics Partnership To Boost Oxford CDC Capacity And Widen Access To Advanced MRI Across The UK 12/2/2025

    Perspectum and InHealth have announced a new national diagnostics partnership that will significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre (CDC).

  4. Siemens Healthineers Advances Coronary Artery Disease Management With Syngo.CT Coronary Cockpit Software 12/2/2025

    At RSNA 2025, Siemens Healthineers announces Syngo.CT Coronary Cockpit1, a new software solution within the Syngo.via2 platform designed to support the management of coronary artery disease (CAD) for both dual-source and photon-counting CT scanners.

  5. A Molecular 'Reset Button' For Reading The Brain Through A Blood Test 12/2/2025

    Tracking how genes switch on and off in the brain is essential for understanding many neurological diseases, yet the tools to monitor this activity are often invasive or unable to capture subtler changes over time.

  6. Roche Receives FDA Clearance With CLIA Waiver And CE Mark For Its First Point-Of-Care Test For Diagnosing Bordetella Infections, Including Whooping Cough (Pertussis) 12/2/2025

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver, in addition to CE IVDR certification.

  7. YD Bio Limited Expands OkaiDx™ Testing Portfolio To Pancreatic And Colorectal Cancer Detection Across The U.S. And Provides Clinical Research Update On Pancreatic Cancer Early Detection 12/2/2025

    YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx™ platform for post‑treatment breast cancer monitoring, detailing the continued expansion of OkaiDx™ blood‑based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection.

  8. Truvian Secures FDA Clearance For TruVerus, Setting A New Standard In Multimodal Blood Testing 12/2/2025

    Truvian Health (“Truvian”) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K251058) for TruVerus, the industry’s first multimodal blood testing benchtop instrument.

  9. Octave Bioscience Forms Strategic Collaboration With Quest Diagnostics To Expand Patient Access To The Octave Multiple Sclerosis Disease Activity (MSDA) Test Across The United States 12/1/2025

    Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced a strategic collaboration with Quest Diagnostics , a leading provider of diagnostic information services, to make the Octave Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest’s nationwide specimen-collection network.

  10. Medimaps Group To Unveil TBS Reveal – Opportunistic Screening AI Software On X-ray – At RSNA 12/1/2025

    Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, today announced the first live presentations of its new software TBS Reveal* at the prestigious Radiological Society of North America (RSNA) 2025 Annual Meeting, taking place in Chicago, IL, from November 30 to December 4.